Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Welsh

Showing results (301-310 of 329) with videos related to

Pageof 33
Sort By:
Diabetologia|December 1, 2017
Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohortRoy Taylor, Wilma S Leslie, Alison C Barnes, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
The Lancet. Diabetes & Endocrinology|March 11, 2019
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trialMichael E J Lean, Wilma S Leslie, Alison C Barnes, et al.
American Heart Journal|February 13, 2026
Exercise treadmill testing for efficacy evaluation in randomized, controlled trialsAndrew Morrow, Robin Young, George R Abraham, et al.
Lancet (London, England)|December 10, 2017
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trialMichael Ej Lean, Wilma S Leslie, Alison C Barnes, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
JACC. Heart Failure|January 2, 2023
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HFCarly Adamson, Paul Welsh, Kieran F Docherty, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
Circulation|December 8, 2018
Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatmentEeva Sliz, Johannes Kettunen, Michael V Holmes, et al.
Circulation|September 1, 2024
Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover TrialAndrew Morrow, Robin Young, George R Abraham, et al.
Pageof 33

Showing results (301-310 of 329) with videos related to

Sort By:
Pageof 33
Diabetologia|December 1, 2017
Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohortRoy Taylor, Wilma S Leslie, Alison C Barnes, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
The Lancet. Diabetes & Endocrinology|March 11, 2019
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trialMichael E J Lean, Wilma S Leslie, Alison C Barnes, et al.
American Heart Journal|February 13, 2026
Exercise treadmill testing for efficacy evaluation in randomized, controlled trialsAndrew Morrow, Robin Young, George R Abraham, et al.
Lancet (London, England)|December 10, 2017
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trialMichael Ej Lean, Wilma S Leslie, Alison C Barnes, et al.
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
JACC. Heart Failure|January 2, 2023
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HFCarly Adamson, Paul Welsh, Kieran F Docherty, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
Circulation|December 8, 2018
Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatmentEeva Sliz, Johannes Kettunen, Michael V Holmes, et al.
Circulation|September 1, 2024
Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover TrialAndrew Morrow, Robin Young, George R Abraham, et al.
Pageof 33